Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: A case report

Hepato-Gastroenterology

Volumn 58, Issue 105, 2011, Pages 161-162

  Ozenne, Violaine ^a   Gervais, Anne ^b   Peytavin, Gilles ^b   Castelnau, Corrine ^a   Valla, Dominique Charles ^a   Degos, Françoise ^a  

^a BEAUJON HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Hepatocellular carcinoma; HIV; Interaction; Side effects; Sorafenib

Indexed keywords

ABACAVIR; ATAZANAVIR; BAY 67 3472; DIDANOSINE; DRUG METABOLITE; LAMIVUDINE; RITONAVIR; SORAFENIB; UNCLASSIFIED DRUG; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; ASTHENIA; CASE REPORT; CD4 LYMPHOCYTE COUNT; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; MALE; NAUSEA; NEEDLE BIOPSY; PRIORITY JOURNAL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DRUG INTERACTIONS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV-1; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 79955008158     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Rosental E, Pialoux G, Bernard N, et al: Liver related death in human-immunodefiency virus-infected patients between 1995 and 2003in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat, 2007;14:183-188.
2. Weber R, Sabin CA, Friis-Moller N, et al: Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study Arch Intern Med 2006;166:1632-1641. (Pubitemid 44232373)
3. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of Sorafenib in patients with advanced hepatocellular carcinoma. J Clinic Oncol 2006;24:4293-4300. (Pubitemid 46630787)
4. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359: 378-390.
5. Strumberg D, Clark JW, Awada A, et al: Safety, pharmacokinetics, and preliminary antitumor activity of Sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. The Oncologist 2007;12:426-437.
6. Clark J, Eder JP, Ryan D, Lathia C, Lenz HJ: Safety and pharmacokinetics of the dual action rafkinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced refractory solid tumors. Clin Cancer Res 2005;11:5472-5480. (Pubitemid 41060823)
7. Von Henting N, Muller A, Rottmann C, et al: Pharmacokinetics of Saquinavir, Atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen. Antimicrobial Agents and Chemotherapy 2007;51:1431-1439.
8. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG: In vitro inhibition of UDP glucuronosyltransferase by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubinglucuronidation. Drug MetabDipos 2005;33:1729-1739.
9. Grandinetti CA, Goldspiel BR: Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy. 2007 Aug; 27:1125-44. (Pubitemid 47173659)